John Tesser

8PUBLICATIONS
36CO-AUTHORS
NanomedicinePharmaceutical delivery technologiesCharacterisation of biological macromoleculesPredictive and prognostic markersPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 22, 2025
Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians.

John R P Tesser, Aline Charabaty, Adelaide A Hebert

|Jun 06, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.

Christopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke

|Apr 15, 2024
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).

Gerd R Burmester, Filip Van den Bosch, John Tesser

|Nov 03, 2023
Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials.

John Tesser, Ahmet Gül, Ewa Olech

|Oct 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.

Bruce Strober, Laura C Coates, Mark G Lebwohl

|Aug 19, 2023
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.

Philip J Mease, Alexis Ogdie, John Tesser

Pageof 2

Frequent Collaborators

4 joint publications

Soumya D Chakravarty

2 joint publications

Joseph F Merola

2 joint publications

May Shawi

2 joint publications

Philip J Mease